BioSpace News Archive

Lone Star Bio

Regulating NIK Activity Emerges as New Way to Enhance Immuno-Oncology Therapies

Regulating the activity of the protein called NF-kappa B-inducing kinase (NIK) is emerging as a new and potentially important way to enhance certain immuno-oncology therapies.

January 11, 2021
·
3 min read
·
Gail Dutton
Business

BDO Report: Biotech CFOs, Optimistic for Recovery, Focus on Digital Transformation

Biotech CFOs, optimistic about economic recovery as COVID-19 vaccines role out, are busy digitally transforming their companies for a post-COVID way of working, according to the 2021 BDO Life Sciences CFO Outlook Survey, released January 11.

January 11, 2021
·
4 min read
·
Gail Dutton
Business

bluebird bio’s Oncology Business Leaves the Nest to Form New Company

Bluebird bio announced plans to split its genetic disease and oncology businesses. Bluebird bio will stay focused on severe genetic disease and spin out its oncology business into a new company.

January 11, 2021
·
3 min read
·
Mark Terry
Policy

New COVID-19 Mutation Could Mess Up Tests, Trigger False Negatives

On Friday, the U.S. Food and Drug Administration (FDA) issued an official alert stating that it could trigger false negatives in COVID-19 tests.

January 11, 2021
·
2 min read
·
Heather McKenzie
Drug Development

Sutro Maximizes Synergy to Treat Cancer and Preserve Quality of Life

While Sutro’s technological platform opens multiple therapeutic doors, the company’s singular focus on homogeneous molecules is a key part of its competitive strategy.

January 11, 2021
·
6 min read
·
Heather McKenzie
Deals

Sanofi Ups Immunology Game With $1.4 Billion Acquisition of Kymab

The deal adds Kymab’s lead asset KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L.

January 11, 2021
·
3 min read
·
Alex Keown
Drug Development

New Study Shows COVID-19 Immunity Can Last at Least Eight Months After Infection

Evidence continues to build for long-lasting immunity to COVID-19 following disease infection, with the publication of a new study showing a durable immune response as far as eight months after the initial onset of symptoms.

January 11, 2021
·
2 min read
·
Mark Zipkin
BioForest

Biopharma Executive Perspectives on 2021

The lessons learned from the global pandemic are expected to translate to existing and emerging therapeutic areas - particularly oncology; more efficient regulatory-industry relationships; mRNA is a word we will continue to hear a lot about; and home health care is here to stay.

January 11, 2021
·
14 min read
·
Heather McKenzie
Drug Development

New Hope for Alzheimer’s Patients as Lilly’s Donanemab Shows Promise in Phase II

The primary endpoint was change from baseline to 76 weeks in the Integrated Alzheimer’s Disease Rating Scale (iADRS).

January 11, 2021
·
3 min read
·
Mark Terry
Business

RNAi-Focused Atalanta Therapeutics Launches to Address CNS Diseases

RNAi-focused Atalanta Therapeutics launched with $110 million in combined Series A funding and collaboration deals with Genentech and Biogen to address diseases related to the central nervous system, including Huntington’s, Alzheimer’s and Parkinson’s diseases.

January 11, 2021
·
3 min read
·
Alex Keown